Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Open accessThe DOI matches its Crossref record; 224 of the 227 references it cites were found in a registry or an index.
Abstract
Apolipoprotein E (APOE) genotype is the major genetic risk factor for Alzheimer disease (AD); the 14 allele increases risk and the 12 allele is protective.In the central nervous system (CNS), apoE is produced by glial cells, is present in high-density-like lipoproteins, interacts with several receptors that are members of the low-density lipoprotein receptor (LDLR) family, and is a protein that binds to the amyloid-b (Ab) peptide.There are a variety of mechanisms by which apoE isoform may influence risk for AD.There is substantial evidence that differential effects of apoE isoform on AD risk are influenced by the ability of apoE to affect Ab aggregation and clearance in the brain.Other mechanisms are also likely to play a role in the ability of apoE to influence CNS function as well as AD, including effects on synaptic plasticity, cell signaling, lipid transport and metabolism, and neuroinflammation.ApoE receptors, including LDLRs, Apoer2, very low-density lipoprotein receptors (VLDLRs), and lipoprotein receptor-related protein 1 (LRP1) appear to influence both the CNS effects of apoE as well as Ab metabolism and toxicity.Therapeutic strategies based on apoE and apoE receptors may include influencing apoE/Ab interactions, apoE structure, apoE lipidation, LDLR receptor family member function, and signaling.Understanding the normal and disease-related biology connecting apoE, apoE receptors, and AD is likely to provide novel insights into AD pathogenesis and treatment.A lzheimer disease (AD), specifically the late- onset form of AD (LOAD), is the most common cause of dementia in individuals older than 60 years of age.Although mutations in the genes PS1, PS2, and APP cause less common forms of early-onset, autosomal dominant familial AD (FAD), these cases represent ,1% of AD.In addition to the genes that cause FAD, LOAD also has a strong genetic component.Although several susceptibility genes for AD have been reported, by far the strongest genetic risk factor for LOAD is apolipoprotein
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those who inherit one copy of the e4 form have about three times the risk of developing Alzheimer's compared with those with two copies of the e3 form, while those who inherit two copies of the e4 form have an estimated eight-to 12-fold risk.[73][74][75]”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, LDLR and LRP1 disruption by PCSK9 may be crucial for AD progression since they are the major ApoE receptors in the brain, are involved in lipid homeostasis and intracellular signaling, and are fundamental for the regulation of neuronal structure and synaptogenesis [79].”
From The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE isoforms may differentially regulate brain lipid metabolism in AD and primary tauopathies.1”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single copy of the ε4 allele increases disease risk by approximately four-fold while two copies of the allele increase disease risk by approximately twelvefold relative to individuals who are ε3/ε3 [1, 4, 5].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the brain most cholesterol is produced de novo by astrocytes, and then transported to neurons and other cells by combining with ApoE, mainly synthesized by astrocytes, to form lipoproteins that are secreted through the ATP-binding cassette (ABC) transporters [9,10].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [9]
Experimental — accuracy not yet measured
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–224 of 224
Nygaard, H. B., & Strittmatter, S. M. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.223 · Cited by 73 · cited 1×
“…al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008; Nygaard and Strittmatter 2009; Gimbel et al. 2010; Palop and Mucke 2010; Renner et al. 2010; Ronicke et al. 2010) (see Mucke and Selkoe 2011).”
BackgroundBoycott, K. M., Bonnemann, C., Herz, J., Neuert, S., Beaulieu, C., Scott, J. N., Venkatasubramanian, A., & Parboosingh, J. S. (2009) · Journal of Child Neurology · doi:10.1177/0883073809332696 · Cited by 71 · cited 1×
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 w w w .p er sp ec ti ve si n m ed ic in e. o rg et al. 1999; May et al. 2004; Boycott et al. 2005; Boycott et al. 2009), may occlude their participation in AD pathogenesis, which would manifest itself much later in life.”
Self-citationFuentealba, R. A., Barría, M. I., Lee, J., Cam, J., Araya, C., Escudero, C. A., Inestrosa, N. C., Bronfman, F. C., Bu, G., & Marzolo, M.-P. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-14 · Cited by 70 · cited 1×
“However, in the absence of common ligands, Apoer2 increases the distribution of APP into lipid rafts and APP processing to Ab (Fuentealba et al. 2007).”
BackgroundSelf-citationBeffert, U., Arguin, C., & Poirier, J. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00888-x · Cited by 67 · cited 2×
“LRP1 has been repeatedly, albeit weakly, associated with AD risk (Beffert et al. 1999; Vazquez-Higuera et al. 2009), and a coding polymorphism in the distantly related Wnt coreceptor LRP6 has also been implicated (De Ferrari et al. 2007).”
Apoer2: a reelin receptor to remember
D’Arcangelo, G. (2005) · Neuron · doi:10.1016/j.neuron.2005.08.001 · Cited by 62
Beffert, U., Aumont, N., Dea, D., Lussier‐Cacan, S., Davignon, J., & Poirier, J. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70041458.x · Cited by 59 · cited 4×
“…in the ligand, the receptors, or the adaptor protein, results in reduced phosphorylation of GSK3b on an inhibitory serine residue, which leads to disinhibition of the enzyme and hyperphosphorylation of tau (Hiesberger et al. 1999; Beffert et al. 2002; Brich et al. 2003; Ohkubo et al. 2003).”
BackgroundInfluentialJSchaefer, E., HHeaton, W., GWetzel, M., et al. (1982) · Arteriosclerosis An Official Journal of the American Heart Association Inc · Cited by 59
Karner, C. M., Dietrich, M. F., Johnson, E. B., Kappesser, N., Tennert, C., Percin, F., Wollnik, B., Carroll, T. J., & Herz, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010418 · Cited by 57 · cited 1×
“…nature of their essential functions during the development of the embryo in general (Herz et al. 1992; Johnson et al. 2005; Dietrich et al. 2010; Karner et al. 2010), and the brain, in particular (Willnow et al. 1996; Trommsdorff 6 Cite this article as Cold Spring Harb Perspect Med…”
BackgroundSelf-citationXu, P., Schmechel, D. E., Qiu, H.-L., Herbstreith, M. H., Rothrock‐Christian, T., Eyster, M. V., Roses, A. D., & Gilbert, J. R. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0213 · Cited by 57 · cited 1×
“Under certain conditions, such as after excitotoxic injury, some neurons appear to be able to synthesize apoE (Xu et al. 1999; Xu et al. 2006).”
Interaction with Amyloid β Peptide Compromises the Lipid Binding Function of Apolipoprotein E
Tamamizu-Kato, S., Cohen, J. K., Drake, C. B., Kosaraju, M. G., Drury, J., & Narayanaswami, V. (2008) · Biochemistry · doi:10.1021/bi702097s · Cited by 57 · cited 2×
“The region of apoE that is responsible for Ab binding is in the carboxy-terminal domain overlapping with the lipid-binding region (Strittmatter et al. 1993b; Tamamizu-Kato et al. 2008), suggesting that the lipophilic Ab peptide associates with apoE in a process that is analogous to lipid binding.”
BackgroundReelin and mDab1 regulate the development of hippocampal connections
Borrell, V., Pujadas, L., Simó, S., Durà, D., Solé, M., Cooper, J. A., del Río, J. A., & Soriano, E. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.06.006 · Cited by 54 · cited 2×
“…studies and observations point toward a role for Reelin and ApoE receptors in the formation of neuronal connections (Del Rio et al. 1997; Borrell et al. 2007) and the generation of dendritic complexity (Trommsdorff et al. 1999; Costa et al. 2001; Niu et al. 2004; Matsuki et al. 2008;…”
Alzheimer pathology of patients carrying apoliprotein E ε4 allele
Heinonen, O. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00076-q · Cited by 52 · cited 1×
“Although some studies reported conflicting findings (Benjamin et al. 1995; Heinonen et al. 1995), a large autopsy study strongly suggested that 14 dosage is associated with increased neuritic plaques in AD (Tiraboschi et al. 2004).”
ResultCellular Catabolism of Lipid Poor Apolipoprotein E via Cell Surface LDL Receptor-Related Protein
Narita, M., Holtzman, D. M., Fagan, A. M., LaDu, M. J., Yu, L., Han, X., Gross, R. W., Bu, G., & Schwartz, A. L. (2002) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a003282 · Cited by 48 · cited 2×
“2005a), whereas recombinant apoE (Narita et al. 2002), apoE-enriched lipoprotein particles (Kowal et al.”
Self-citationDietrich, M. F., van der Weyden, L., Prosser, H. M., Bradley, A., Herz, J., & Adams, D. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009960 · Cited by 46 · cited 2×
“The very nature of their essential functions during the development of the embryo in general (Herz et al. 1992; Johnson et al. 2005; Dietrich et al. 2010; Karner et al. 2010), and the brain, in particular (Willnow et al. 1996; Trommsdorff 6 Cite this article as Cold Spring Harb Perspect Med…”
Self-citationApolipoprotein E decreases tau kinases and phospho-tau levels in primary neurons.
Hoe, H.-S., Freeman, J., & Rebeck, G. W. (2006) · Molecular Neurodegeneration · doi:10.1186/1750-1326-1-18 · Cited by 45 · cited 4×
“However, they harbor a variety of short conserved sequence stretches, such as the tetra-amino acid NPxY motif, which serve as docking sites for a wide array of cytoplasmic adaptor and scaffolding proteins (Trommsdorff et al. 1998; Gotthardt et al. 2000; Beffert et al. 2005; Hoe et al. 2006a; Hoe et al. 2006b).”
InfluentialReceptor-associated Protein Interacts with Amyloid-β Peptide and Promotes Its Cellular Uptake
Kanekiyo, T., & Bu, G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.015032 · Cited by 44 · cited 3×
“The important function of LRP1 in brain Ab clearance was shown in amyloid mouse model with decreased LRP1 expression owing to a deletion of their chaperone RAP (Van Uden et al. 2002).”
BackgroundSelf-citationStolt, P. C., Chen, Y., Liu, P., Bock, H. H., Blacklow, S. C., & Herz, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413356200 · Cited by 42 · cited 2×
“The simultaneous interaction of the adapter protein Disabled 1 (Dab1) with NPxY motifs in their intracellular domains (ICDs) (Trommsdorff et al. 1998; Stolt et al. 2005) results in the progressive recruitment and transphosphorylation of Src family tyrosine kinases (SFKs) (Howell et al.”
Self-citationBenjamin, R., Leake, A., Ince, P. G., Perry, R. H., McKeith, I. G., Edwardson, J. A., & Morris, C. M. (1995) · Neurodegeneration · doi:10.1006/neur.1995.0053 · Cited by 37 · cited 2×
“Although some studies reported conflicting findings (Benjamin et al. 1995; Heinonen et al. 1995), a large autopsy study strongly suggested that 14 dosage is associated with increased neuritic plaques in AD (Tiraboschi et al.”
Chai, X., Förster, E., Zhao, S., Bock, H. H., & Frotscher, M. (2009) · Communicative & Integrative Biology · doi:10.4161/cib.2.4.8614 · Cited by 34 · cited 7×
“Reelin induces the phosphorylation of ncofilin at the inhibitory Ser3 residue, thereby promoting spine stability (Chai et al. 2009; Frotscher 2010).”
InfluentialHone, E., Martins, I. J., Jeoung, M., Ji, T. H., Gandy, S. E., & Martins, R. N. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7406 · Cited by 30 · cited 1×
“Furthermore, Ab peptides modulate the binding of apoE isoforms differently to apoE receptors (Beffert et al. 1998; Hone et al. 2005).”
BackgroundVázquez‐Higuera, J. L., Mateo, I., Sánchez‐Juan, P., Rodríguez‐Rodríguez, E., Pozueta, A., Infante, J., Berciano, J., & Combarros, O. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000234913 · Cited by 28 · cited 2×
“LRP1 has been repeatedly, albeit weakly, associated with AD risk (Beffert et al. 1999; Vazquez-Higuera et al. 2009), and a coding polymorphism in the distantly related Wnt coreceptor LRP6 has also been implicated (De Ferrari et al. 2007).”
Differential functions of the Apoer2 intracellular domain in selenium uptake and cell signaling
Masiulis, I., Quill, T. A., Burk, R. F., & Herz, J. (2009) · bchm · doi:10.1515/bc.2009.011 · Cited by 26 · cited 2×
“2006b) are not caused by selenium depletion, but by the loss of NMDA and AMPA receptor regulation (Masiulis et al. 2009).”
Self-citationDiagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2
Self-citationCole (2000) · doi:10.1002/1097-0029(20000815)50:4<316::aid-jemt11>3.0.co;2-e · cited 1×
“Data from in vitro studies support the idea that apoE facilitates the binding and internalization of soluble Ab by cells or its clearance via enzymes such as neprilysn (Beffert et al. 1998; Yang et al. 1999; Cole and Ard 2000; Koistinaho et al. 2004; Jiang et al. 2008).”
Background
Research works printed but not linked: 1
- Sanan DA, Weisgraber KH, Russel SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewksi T, Frangione B, Roses B, et al. 1994. Apolipoprotein E associates with b amyloid peptide of Alzheimer's disease to form novel monofibrils. J Clin Invest 94: 860 -869.
Cited by
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
“Those who inherit one copy of the 34 form have a three-fold higher risk of developing Alzheimer’s than those without the 34 form, while those who inherit two copies of the 34 form have an 8- to 12-fold higher risk [40,42,43].”
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
2022 Alzheimer's disease facts and figures
(2022) · Alzheimer's & Dementia · doi:10.1002/alz.12638 · Cited by 2,341
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
Metadata
- Authors
- Holtzman, D. M., Herz, J., & Bu, G.
- Affiliations
- Washington University in St. Louis (US)
- The University of Texas at Dallas (US)
- Mayo Clinic in Florida (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-01-10
- Volume
- 2
- Issue
- 3
- Pages
- a006312-a006312
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3282491
- OpenAlex
- W2143955562
- Cited by
- 782
- References
- 227
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 39 · 2023: 51 · 2022: 76 · 2021: 79 · 2020: 67 · 2019: 66 · 2018: 51 · 2017: 51 · 2016: 60 · 2015: 42 · 2014: 59 · 2013: 41 · 2012: 14
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (P01AG030128, R01AG027924, R01AG031784, R01AG035355)
- National Heart, Lung, and Blood Institute (R37HL063762)
- National Institute of Neurological Disorders and Stroke (R37NS034467, P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE isoforms, Alzheimer's disease, APOE ε4, APOE2, apoE receptors, low-density lipoprotein receptor family, ApoER2, VLDLR, LRP1, amyloid-beta, amyloid-beta aggregation, amyloid-beta clearance, lipid modification, synaptic plasticity, neuroinflammation, lipid transport, genetic risk factors, treatment options
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain, Carrier Proteins, Humans, Neuronal Plasticity, Phosphorylation, Amyloid beta-Peptides, Polymorphism, Single Nucleotide, Protein Transport, Low Density Lipoprotein Receptor-Related Protein-1, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.